Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924169 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01924169: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01924169 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01924169, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if lenalidomide can increase the level of immunoglobulins (parts of the blood that may help to improve the immune system's function) and/or will improve the protective effect of the flu and pneumonia vaccines in patients with CLL.
Primary Outcome
IgG response defined as having improvement in IgG level by at least 25% at 6 months, compared to baseline.
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Influenza Vaccine
- BIOLOGICAL Pneumovax Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-11-24 |
| Est. Completion | 2017-02-21 |
| Phase | Phase 2 |
Why NCT01924169 stopped before completion
NCT01924169 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Lenalidomide is the first listed.
NCT01924169 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01924169 about?
NCT01924169 is a clinical study titled "Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)". The goal of this clinical research study is to learn if lenalidomide can increase the level of immunoglobulins (parts of the blood that may help to improve the immune system's function) and/or will improve the protective effect of the flu and pneumonia vaccines in patients with CLL.
What is the current status of trial NCT01924169?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-11-24. Estimated completion is 2017-02-21.
What interventions are being tested in trial NCT01924169?
The interventions under investigation include: Lenalidomide (DRUG), Influenza Vaccine (BIOLOGICAL), Pneumovax Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01924169?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01924169's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI